ANTIDEPRESSANT USE IN CHILDREN & ADOLESCENTS WITH CHRONIC KIDNEY DISEASE



Your patient has chronic kidney disease (CKD). This handout provides information about dosing adjustments if antidepressants are required. The information is provided as a guide. If you have a patient specific question, please contact your patient's nephrologist or care team. References can be found in the full guideline, "Depression and Anxiety: The Role of Kidney Care Clinics" at bcrenalagency.ca.

Medications	Dosing adjustment in renal failure				
	eGFR 30-60 mL/min	eGFR 15-30 mL/min	eGFR less than 15 mL/min	Dialysis (PD or HD)	Comments
			1 st line the	rapies	
		Selecti	ive Serotonin Reup	take Inhibitors (SSRI)	
Citalopram	No adjustment	No adjustment	No adjustment	No adjustment (HD: not removed)	Safe in CV disease but risk of QTc prolongation (Max 40 mg/d or 20 mg/c w/ strong CYP2C19 inhibitors) Half as potent as escitalopram, therefore NOT interchangeable
Escitalopram	No adjustment	SD: 10 mg/day, ↑ carefully	SD: 10 mg/day, ↑ carefully	SD: 10 mg/day, ↑ carefully (HD: not removed)	Safe in CV disease but risk of QTc prolongation (Max 20 mg/d) Twice as potent as citalopram, therefore NOT interchangeable
Fluoxetine	No adjustment	No adjustment	No adjustment	No adjustment (HD: not removed)	Risk of QTc prolongation
Fluvoxamine	No adjustment	No adjustment	No adjustment	No adjustment (HD: partially removed)	Children: Max 200 mg/d Adolescents: Max 300 mg/d
Sertraline	No adjustment	SD: 50 mg/day ↑ carefully	SD: 25 mg/day consider Ψ max	SD: 25 mg/day consider Ψ max (HD: not removed)	Safe in pts with CV disease
			Non - 1 st line	therapies	
		Serotonin	/Norepinephrine Re	euptake Inhibitors (SN	IRI)
Duloxetine	No adjustment	SD: 30 mg/day,	SD: 30 mg/day,	SD: 30 mg/day, ↑ carefully	Consider for concomitant peripheral neuropathy (no data in C&A)
Venlafaxine	No adjustment	37.5-112.5 mg/day	37.5-112.5 mg/day	37.5-112.5 mg/day	Consider for concomitant peripheral neuropathy (no data in C&A)
		Seroto	nin Antagonist/Reu	ptake Inhibitor (SARI)	
Trazodone	Dose adjustment not required when dosed at 25-50 mg HS for insomnia; higher doses (150-600 mg) virtually never prescribed for depression in C&A				Theoretical risk for serotonin syndrom when combined with SSRI/SNRIs but clinically of little concern at dose of 25-50 mg HS
			Other Antidep	oressants	
Bupropion ⁸	Max: 150 mg/day	Max: 150 mg/day	Max: 150 mg/day	Max: 150 mg/day every third day (HD: not removed)	Non-sedating, may cause insomnia, not associated with weight gain Risk of accumulation of toxic metabolites causing dysrhythmia (wide QRS complex) in renal failure
Mirtazapine	No adjustment	15 mg/day, ↑ carefully	15 mg/day, ↑ carefully	15 mg/day, ↑ carefully (HD: partially removed)	Has been used for pruritus management (adults) A choice for concomitant insomnia (dose: 7.5-15 mg HS)

Abbreviations: CV: cardiovascular; eGFR: estimated Glomerular Filtration Rate; HD: hemodialysis; HS: at bedtime; Max: maximum dose, N/V/D: nausea/vomiting/diarrhea; PD: peritoneal dialysis; SD: starting dose; ↑ increase; ✔ decrease





fraserhealth



BC Provincial Renal Agency (BCPRA) 700-1380 Burrard Street Vancouver, BC

Phone: 604-875-7340 Email: bcpra@bcpra.ca Web: BCRenalAgency.ca



Youtube.com/BCRenalAgency